Bioorganic & Medicinal Chemistry, Journal Year: 2025, Volume and Issue: unknown, P. 118238 - 118238
Published: May 1, 2025
Language: Английский
Journal of Nanobiotechnology, Journal Year: 2025, Volume and Issue: 23(1)
Published: Jan. 22, 2025
Photoimmunotherapy, which combines phototherapy with immunotherapy, exhibits significantly improved therapeutic effects compared mono-treatment regimens. However, its use is associated drawbacks, such as insufficient reactive oxygen species (ROS) production and uneven photosensitizer distribution. To address these issues, we developed a controllable, targeted nanosystem that enhances oxidative stress through multiple pathways, achieving synergistic photothermal, photodynamic, immunotherapy for tumor treatment. These nanoparticles (D/I@HST NPs) accurately target overexpressed transferrin receptors (TfRs) on the surface of cells surface-modified (Tf). After endocytosis, D/I@HST NPs generate ROS under 808-nm laser irradiation, breaking ROS-responsive crosslinking agent increasing drug release utilization. Tf also carries Fe3+, reduced to Fe2+ by iron reductase in acidic microenvironment (TME). Consequently, endoperoxide bridge structure dihydroartemisinin cleaved, causing additional generation. Furthermore, released IR-780 exerts both photodynamic photothermal effects, enhancing cell death. This multi-pathway amplification effect can trigger immunogenic death tumors, promoting relevant antigens damage-associated molecular patterns, thereby dendritic maturation sensitivity immunotherapy. Mature transmit signals T cells, infiltration activation, facilitating growth inhibition suppression lung metastasis. myeloid-derived suppressor decreases after In summary, this stress-amplified effectively inhibits reverses immunosuppressive microenvironment, provides new insights into combined phototherapy.
Language: Английский
Citations
3
Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 15
Published: Jan. 14, 2025
In recent years, significant breakthroughs have been made in cancer therapy, particularly with the development of molecular targeted therapies and immunotherapies, owing to advances tumor biology immunology. High-grade gliomas (HGGs), characterized by their high malignancy, remain challenging treat despite standard treatment regimens, including surgery, radiotherapy, chemotherapy, treating fields (TTF). These provide limited efficacy, highlighting need for novel strategies. Molecular immunotherapy emerged as promising avenues improving outcomes high-grade gliomas. This review explores current status advancements immunotherapeutic approaches
Language: Английский
Citations
2
Drug Resistance Updates, Journal Year: 2025, Volume and Issue: 81, P. 101215 - 101215
Published: Feb. 26, 2025
Language: Английский
Citations
1
Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16
Published: March 5, 2025
Cannabinoids relieve pain, nausea, anorexia and anxiety, improve quality of life in several cancer patients. The immunotherapy with checkpoint inhibitors (ICIs), although very successful a subset patients, is accompanied by moderate to severe immune-related adverse events (ir-AE) that often necessitate its discontinuation. Because their role symptomatic relief, cannabinoids have been used combination immune inhibitor (ICI) immunotherapy. A few studies strongly suggest the use medicinal cannabis patients attenuates many ir-AE associated ICI increase tolerability. However, no significant beneficial effects on overall survival, progression free survival or relapses were observed; rather, some noted concurrent administration clinical benefits latter. cannabinoids' well documented immunosuppressive mediated through cannabinoid recptor-2 (CB2), we propose considering this receptor as an inhibitory per se. simultaneous neutralization CB2, treatment, may lead better outcomes receiving In regard, such cannabidiol (CBD) cannabigerol (CBG), little agonism for be therapeutic choices. Additional strategies e.g., monoacylglycerol lipase (MAGL) degrade endocannabinoids lipogenesis formation lipid bilayers cells also explored. Future should take into consideration gut microbiota, CYP450 polymorphism haplotypes, cannabinoid-drug interactions genetic somatic variations occurring receptors signaling pathways personalized cannabis-based therapies ICIs. This rational knowledge-based regimens tailored individual
Language: Английский
Citations
1
BioDrugs, Journal Year: 2025, Volume and Issue: unknown
Published: March 19, 2025
Language: Английский
Citations
1
Cell investigation., Journal Year: 2024, Volume and Issue: 1(1), P. 100004 - 100004
Published: Nov. 5, 2024
Language: Английский
Citations
6
Oral Oncology Reports, Journal Year: 2024, Volume and Issue: unknown, P. 100652 - 100652
Published: Sept. 1, 2024
Language: Английский
Citations
4
Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 14
Published: Jan. 7, 2025
Gastrointestinal (GI) cancers represent a significant global health burden, and the need for more effective treatment options is exceptionally pressing. The present meta-analysis aimed to explore efficacy safety of combination nivolumab ipilimumab in treating GI cancers. A systematic search four databases (PubMed, Embase, Web Science, Cochrane Library) was conducted articles on with combined ipilimumab, published from 2014 up 30 August 2024. inclusion criteria were designed according principles Participants, Intervention, Control, Outcomes, Study (PICOS). control group chemotherapy or monotherapy other drugs. We extracted data 10 randomized controlled trials utilized random effects model assess objective response rate (ORR), median progression-free survival (mPFS), overall (mOS), duration (mDOR), treatment-related adverse events (TRAEs). analysis using Review Manager version 5.4 Stata 12.0. Overall, demonstrated superior outcomes, including higher ORR (OR = 1.69, P 0.01), prolonged mOS (MD 1.74, 0.04) extended mDOR 5.64, < 0.00001) compared group. Subgroup that 1.75, 0.02) 5.02, 0.003) significantly improved patients esophageal cancer. Notably, biliary cancer lower 0.11, 0.04). Additionally, NIVO1 + IPI3group 2.82, 0.01) NIVO3 IPI1 1.62, 0.01). Regarding safety, there no statistically difference between regimen terms any grade 0.72, 0.26) 3-4 TRAEs 1.36, 0.14). Nivolumab (especially cancer) without causing reactions. However, its still needs be further proven. https://www.crd.york.ac.uk/prospero/, identifier CRD42024590994.
Language: Английский
Citations
0
Critical Reviews in Oncology/Hematology, Journal Year: 2025, Volume and Issue: unknown, P. 104628 - 104628
Published: Jan. 1, 2025
Language: Английский
Citations
0
npj Precision Oncology, Journal Year: 2025, Volume and Issue: 9(1)
Published: Jan. 24, 2025
Abstract We report the basal cell cancer (BCC) cohort of SWOG/NCI 1609 Dual Anti-CTLA-4 & Anti-PD-1 blockade in Rare Tumors (DART), a phase II prospective, multicenter basket trial nivolumab and ipilimumab. The primary endpoint was objective response rate (ORR) (RECIST v1.1). Overall survival (OS), progression-free (PFS), toxicity were secondary endpoints. Sixteen patients with advanced/metastatic BCC evaluable. ORR 31% (95% CI, 19–50%), 12-month OS, 75% 57–100%). Median PFS 9.3 months 3.3–NA). Of 15 evaluable for clinical benefit, five partial responses (PRs) stable disease >6 (total = 10/15 (66.7%)) seen. most common toxicities included fatigue (37.5%), pruritis (31.3%), diarrhea (25%). In BCC, ipilimumab produced an prolonged (>6 months) 73% patients, seven PFS/iPFS >1 year, including one prior anti-PD-1. ClinicalTrials.gov ID: NCT02834013 (Registered 7/15/2016; https://clinicaltrials.gov/ct2/show/NCT02834013 ).
Language: Английский
Citations
0